We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Genetic Determinants of Opioids Analgesia

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: September 27, 2005
Last Update Posted: October 29, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Hadassah Medical Organization

The response to opioids varies greatly among individuals. Some of these variability is accounted for by genetic factors.

The present study was designed to evaluate the possibility that genetic polymorphism in the gene encoding for mu opioid receptor may explain variability in the response to alfentanil during lithotripsy.

Condition Intervention
Nephrolithiasis Drug: Alfentanil

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effect of mu Opioid Receptor Polymorphism on the Response to Alfentanil During Lithotripsy

Resource links provided by NLM:

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • Total alfentanil dose used during the procedure.
  • The extent of respiratory depression.

Estimated Enrollment: 100
Study Start Date: August 1997

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age > 20

Exclusion Criteria:

  • Regular use of opioid drugs
  • Known hypersensitivity to alfentanil
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00226564

Hadassah Medical Organization
Jerusalem, Israel
Sponsors and Collaborators
Hadassah Medical Organization
Principal Investigator: Yoseph Caraco, MD Hadassah Medical Organization
  More Information

ClinicalTrials.gov Identifier: NCT00226564     History of Changes
Other Study ID Numbers: yc19554-HMO-CTIL
First Submitted: September 12, 2005
First Posted: September 27, 2005
Last Update Posted: October 29, 2008
Last Verified: October 2008

Additional relevant MeSH terms:
Kidney Calculi
Kidney Diseases
Urologic Diseases
Urinary Calculi
Pathological Conditions, Anatomical
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anesthetics, Intravenous
Anesthetics, General